eResearchTechnology, Inc., commonly known as ERT, is a leading provider of technology and services for the pharmaceutical and biotechnology industries. Headquartered in the United States, ERT operates across major regions, including Europe and Asia, delivering innovative solutions that enhance clinical trial processes. Founded in 1977, the company has achieved significant milestones, including the integration of advanced data collection technologies. ERT's core offerings encompass cardiac safety, respiratory, and eSource solutions, distinguished by their commitment to accuracy and reliability. The company is recognised for its robust market position, having supported thousands of clinical trials globally. With a focus on improving patient outcomes and streamlining trial efficiency, ERT continues to set industry standards in clinical research technology.
How does eResearchTechnology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
eResearchTechnology, Inc.'s score of 43 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
eResearchTechnology, Inc., headquartered in the US, has not publicly disclosed any specific carbon emissions data as of the latest reporting period. However, the company has made significant climate commitments aimed at reducing its greenhouse gas emissions across all scopes. eResearchTechnology has set ambitious near-term targets to reduce absolute Scope 1 and Scope 2 emissions by approximately 63.6% by 2030, using 2021 as the baseline year. Additionally, the company aims to cut its absolute Scope 3 emissions by about 25% within the same timeframe. Looking towards the long term, eResearchTechnology is committed to achieving a remarkable 90% reduction in absolute emissions across all scopes (1, 2, and 3) by 2045. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. The company's commitment to reach net-zero greenhouse gas emissions by 2045 underscores its dedication to sustainability and climate action within the pharmaceuticals, biotechnology, and life sciences sector.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
eResearchTechnology, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.